Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Thiamidol** is a proprietary, patented active ingredient developed by Beiersdorf, primarily used in skincare for the treatment of hyperpigmentation disorders, including melasma, solar lentigines, and post-inflammatory hyperpigmentation. It acts as a potent, reversible inhibitor of human tyrosinase, an enzyme critical in the synthesis of melanin, thereby reducing the formation and accumulation of pigment spots. Thiamidol has shown superior efficacy when compared to traditional agents like hydroquinone, with notable reductions in MASI scores and high rates of patient improvement[1][3][4][9]. Its safety profile is suitable for long-term, over-the-counter use, with minimal adverse effects, making it appropriate for sensitive and diverse skin types[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thiamidol.